Dr. Reddy's Laboratories Ltd gets Form 483 with 4 observations from USFDA for Srikakulam formulations facility

The United States Food & Drug Administration (USFDA) today completed a product-specific Pre-Approval Inspection (PAI) and a routine GMP inspection at our formulations manufacturing facility in Srikakulam (FTO SEZ PU2). The inspection was conducted from 8th May, 2023 to 12th May, 2023. We have been issued a Form 483 with four observations, which we will address within the stipulated timeline.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4532.40 as compared to the previous close of Rs. 4868.00. The total number of shares traded during the day was 79805 in over 12155 trades.

The stock hit an intraday high of Rs. 4702.45 and intraday low of 4523.25. The net turnover during the day was Rs. 365063321.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 USFDA Inspection Srikakulam Form483 4Observations